BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld MedTech
Home
» Disappointed Endologix stumbles as FDA calls for more Nellix EVAS system data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Disappointed Endologix stumbles as FDA calls for more Nellix EVAS system data
Nov. 18, 2016
By
Liz Hollis
No Comments
A "disappointed" Endologix Inc. (Nasdaq:ELGX) now is anticipating a second quarter 2018 approval of the Nellix endovascular aneurysm sealing (EVAS) system following the FDA's request for two-year patient follow-up data.
BioWorld MedTech